NCT03292185View on ClinicalTrials.gov

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

January 2, 2018

Study Completion Date

January 2, 2018

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec/liraglutide

Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.

DRUG

insulin degludec

17 U Insulin Degludec, single dose administration under the skin in the thigh.

DRUG

liraglutide

0.6 mg Liraglutide, single dose administration under the skin in the thigh

Trial Locations (1)

100032

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter